Table 1.
Comparisons of baseline characteristics between ACPA-negative [ACPA (−)] and ACPA-positive [ACPA (+)] groups.
| N | ACPA (−) | ACPA (+) | p value |
|---|---|---|---|
| 107 | 447 | ||
| Age (years) | 67.3 ± 13.7 | 68.0 ± 11.3 | 0.583 |
| Sex (% female) | 82.2 | 79.0 | 0.451 |
| Disease duration (years) | 10.4 ± 10.1 | 12.5 ± 11.9 | 0.082 |
| Body weight (kg) | 51.9 ± 11.4 | 51.1 ± 9.1 | 0.412 |
| ACPA (U/mL) | 4.5 ± 4.2 | 370.8 ± 545.1 | < 0.001 |
| RF positive (%) | 44.6 | 82.7 | < 0.001 |
| eGFR | 71.8 ± 24.9 | 73.4 ± 25.0 | 0.547 |
| KL-6 (U/mL) | 308.6 ± 263.9 | 339.3 ± 272.6 | 0.367 |
| Concomitant MTX use (%) | 49.0 | 41.2 | 0.162 |
| MTX dose (mg/week)a | 9.0 ± 3.0 | 8.6 ± 3.5 | 0.550 |
| Oral PSL use (%) | 44.9 | 52.9 | 0.160 |
| Oral PSL dose (mg/day)a | 5.6 ± 3.1 | 5.5 ± 3.3 | 0.881 |
| Previous biologics (%) | 68.2 | 72.0 | 0.434 |
| No. previous biologicsa | 1.5 ± 0.9 | 1.6 ± 0.8 | 0.813 |
| SDAI | 20.8 ± 14.0 | 22.2 ± 12.7 | 0.381 |
| TJC, 0–28 | 5.6 ± 5.7 | 5.5 ± 5.2 | 0.796 |
| SJC, 0–28 | 4.5 ± 4.6 | 4.9 ± 4.7 | 0.485 |
| PtGA, 0–10 cm | 4.9 ± 2.8 | 5.2 ± 2.6 | 0.238 |
| PhGA, 0–10 cm | 4.1 ± 2.6 | 4.2 ± 2.2 | 0.682 |
| CRP (mg/dL) | 2.0 ± 2.6 | 2.4 ± 3.9 | 0.326 |
| MMP-3 (ng/mL) | 191.9 ± 243.2 | 190.8 ± 200.8 | 0.966 |
| mHAQ | 0.85 ± 0.71 | 0.83 ± 0.68 | 0.860 |
| mTSS | 64.0 ± 65.8 | 71.8 ± 87.7 | 0.631 |
ACPA anti-citrullinated protein/peptide antibody, RF rheumatoid factor, eGFR estimated glomerular filtration rate, KL-6 Krebs von den Lungen-6, MTX methotrexate, PSL prednisolone, SDAI simplified disease activity index, TJC tender joint count, SJC swollen joint count, PtGA patient’s global assessment, PhGA physician’s global assessment, CRP C-reactive protein, MMP-3 matrix metalloproteinase-3, mHAQ modified health assessment questionnaire, mTSS van der Heijde modified total Sharp score.
aMean among patients receiving the drug.